Barinthus Biotherapeutics Plc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Barinthus Biotherapeutics Plc. on September 5, 2024, reporting events occurring on September 1, 2024. The Company is an emerging growth company incorporated in England and Wales, with its American Depositary Shares trading on The Nasdaq Global Market under the symbol BRNS.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive personnel changes and does not contain financial statements or performance metrics.
Material Changes
The primary material change reported is the promotion of Graham Griffiths from Chief Business Officer to Chief Operating Officer, effective September 1, 2024. In connection with this promotion, Mr. Griffiths' annual salary was increased to £336,144. There are no reported changes to the Company's capital structure, debt levels, or operational scope in this filing.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, or specific risks. It confirms there are no family relationships between Mr. Griffiths and other directors or officers, and no related person transactions exist between Mr. Griffiths and the Company.
Key Facts for Investor Verification
- Executive Promotion: Graham Griffiths has been promoted to Chief Operating Officer.
- Compensation Adjustment: Mr. Griffiths' salary is now £336,144 effective September 1, 2024.
- Tenure: Mr. Griffiths has served as Chief Business Officer since October 2017.
- Related Party Status: The Company confirms no related person transactions or family relationships involving Mr. Griffiths.